Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253394 · ClinicalTrials.gov registry record · Phase 4
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT02253394: Clinical Trial Phase 4 study, sponsored by Brigham and Women's Hospital.
NCT02253394 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02253394, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity. We also want to find out if spironolactone and ambrisentan effect the cardiac output (amount of blood the heart pumps every minute), right ventricle function and quality of life.
Primary Outcome
Study the effect of combination ambrisentan (5-10 mg/d) + spironolactone (50 mg/d) on pVO2 and cardiac output. The pVO2 refers to a measure of general physical fitness measured during exercise.
Interventions
- DRUG Ambrisentan plus Spironolactone
- DRUG Ambrisentan plus Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-02 |
| Phase | Phase 4 |
Why NCT02253394 stopped before completion
NCT02253394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Ambrisentan plus Spironolactone is the first listed.
NCT02253394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02253394 about?
NCT02253394 is a clinical study titled "The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study". The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity. We also want to find out if spironolactone and ambrisentan effect the cardiac output (amount of blood the heart pumps every minute), right ventri...
What is the current status of trial NCT02253394?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2015-09. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02253394?
The interventions under investigation include: Ambrisentan plus Spironolactone (DRUG), Ambrisentan plus Placebo (DRUG).
Who is sponsoring clinical trial NCT02253394?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02253394's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia